Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2

James F. Blake, John J. Gaudino, Jason De Meese, Peter Mohr, Mark Chicarelli, Hongqi Tian, Rustam Garrey, Allen Thomas, Christopher S. Siedem, Michael B. Welch, Gabrielle Kolakowski, Robert Kaus, Michael Burkard, Matthew Martinson, Huifen Chen, Brian Dean, Danette A. Dudley, Stephen E. Gould, Patricia Pacheco, Sheerin Shahidi-LathamWeiru Wang, Kristina West, Jianping Yin, John Moffat, Jacob B. Schwarz

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The discovery and optimization of a series of tetrahydropyridopyrimidine based extracellular signal-regulated kinase (Erks) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent and selective inhibition of Erk2 and knockdown of phospho-RSK levels in HepG2 cells and tumor xenografts.

Original languageEnglish (US)
Pages (from-to)2635-2639
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Volume24
Issue number12
DOIs
StatePublished - Jun 15 2014

Fingerprint

Drug Design
Extracellular Signal-Regulated MAP Kinases
Hep G2 Cells
Heterografts
Tumors
Pharmaceutical Preparations
Neoplasms
pyrimidine

Keywords

  • Erk2 kinase inhibitors
  • Mek resistance
  • Structure based drug design

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Blake, J. F., Gaudino, J. J., De Meese, J., Mohr, P., Chicarelli, M., Tian, H., ... Schwarz, J. B. (2014). Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2. Bioorganic and Medicinal Chemistry Letters, 24(12), 2635-2639. https://doi.org/10.1016/j.bmcl.2014.04.068

Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2. / Blake, James F.; Gaudino, John J.; De Meese, Jason; Mohr, Peter; Chicarelli, Mark; Tian, Hongqi; Garrey, Rustam; Thomas, Allen; Siedem, Christopher S.; Welch, Michael B.; Kolakowski, Gabrielle; Kaus, Robert; Burkard, Michael; Martinson, Matthew; Chen, Huifen; Dean, Brian; Dudley, Danette A.; Gould, Stephen E.; Pacheco, Patricia; Shahidi-Latham, Sheerin; Wang, Weiru; West, Kristina; Yin, Jianping; Moffat, John; Schwarz, Jacob B.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 24, No. 12, 15.06.2014, p. 2635-2639.

Research output: Contribution to journalArticle

Blake, JF, Gaudino, JJ, De Meese, J, Mohr, P, Chicarelli, M, Tian, H, Garrey, R, Thomas, A, Siedem, CS, Welch, MB, Kolakowski, G, Kaus, R, Burkard, M, Martinson, M, Chen, H, Dean, B, Dudley, DA, Gould, SE, Pacheco, P, Shahidi-Latham, S, Wang, W, West, K, Yin, J, Moffat, J & Schwarz, JB 2014, 'Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2', Bioorganic and Medicinal Chemistry Letters, vol. 24, no. 12, pp. 2635-2639. https://doi.org/10.1016/j.bmcl.2014.04.068
Blake, James F. ; Gaudino, John J. ; De Meese, Jason ; Mohr, Peter ; Chicarelli, Mark ; Tian, Hongqi ; Garrey, Rustam ; Thomas, Allen ; Siedem, Christopher S. ; Welch, Michael B. ; Kolakowski, Gabrielle ; Kaus, Robert ; Burkard, Michael ; Martinson, Matthew ; Chen, Huifen ; Dean, Brian ; Dudley, Danette A. ; Gould, Stephen E. ; Pacheco, Patricia ; Shahidi-Latham, Sheerin ; Wang, Weiru ; West, Kristina ; Yin, Jianping ; Moffat, John ; Schwarz, Jacob B. / Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2. In: Bioorganic and Medicinal Chemistry Letters. 2014 ; Vol. 24, No. 12. pp. 2635-2639.
@article{c5058960180945f485448044545ce5a4,
title = "Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2",
abstract = "The discovery and optimization of a series of tetrahydropyridopyrimidine based extracellular signal-regulated kinase (Erks) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent and selective inhibition of Erk2 and knockdown of phospho-RSK levels in HepG2 cells and tumor xenografts.",
keywords = "Erk2 kinase inhibitors, Mek resistance, Structure based drug design",
author = "Blake, {James F.} and Gaudino, {John J.} and {De Meese}, Jason and Peter Mohr and Mark Chicarelli and Hongqi Tian and Rustam Garrey and Allen Thomas and Siedem, {Christopher S.} and Welch, {Michael B.} and Gabrielle Kolakowski and Robert Kaus and Michael Burkard and Matthew Martinson and Huifen Chen and Brian Dean and Dudley, {Danette A.} and Gould, {Stephen E.} and Patricia Pacheco and Sheerin Shahidi-Latham and Weiru Wang and Kristina West and Jianping Yin and John Moffat and Schwarz, {Jacob B.}",
year = "2014",
month = "6",
day = "15",
doi = "10.1016/j.bmcl.2014.04.068",
language = "English (US)",
volume = "24",
pages = "2635--2639",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2

AU - Blake, James F.

AU - Gaudino, John J.

AU - De Meese, Jason

AU - Mohr, Peter

AU - Chicarelli, Mark

AU - Tian, Hongqi

AU - Garrey, Rustam

AU - Thomas, Allen

AU - Siedem, Christopher S.

AU - Welch, Michael B.

AU - Kolakowski, Gabrielle

AU - Kaus, Robert

AU - Burkard, Michael

AU - Martinson, Matthew

AU - Chen, Huifen

AU - Dean, Brian

AU - Dudley, Danette A.

AU - Gould, Stephen E.

AU - Pacheco, Patricia

AU - Shahidi-Latham, Sheerin

AU - Wang, Weiru

AU - West, Kristina

AU - Yin, Jianping

AU - Moffat, John

AU - Schwarz, Jacob B.

PY - 2014/6/15

Y1 - 2014/6/15

N2 - The discovery and optimization of a series of tetrahydropyridopyrimidine based extracellular signal-regulated kinase (Erks) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent and selective inhibition of Erk2 and knockdown of phospho-RSK levels in HepG2 cells and tumor xenografts.

AB - The discovery and optimization of a series of tetrahydropyridopyrimidine based extracellular signal-regulated kinase (Erks) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent and selective inhibition of Erk2 and knockdown of phospho-RSK levels in HepG2 cells and tumor xenografts.

KW - Erk2 kinase inhibitors

KW - Mek resistance

KW - Structure based drug design

UR - http://www.scopus.com/inward/record.url?scp=84900821225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900821225&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2014.04.068

DO - 10.1016/j.bmcl.2014.04.068

M3 - Article

C2 - 24813737

AN - SCOPUS:84900821225

VL - 24

SP - 2635

EP - 2639

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 12

ER -